Aflibercept for untreated retinopathy in babies born preterm TS ID 11943Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Avatrombopag for treating primary chronic immune thrombocytopenia in people 1 to 17 years [TSID12109]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Baloxavir marboxil for treating influenza in babies under 1 year [ID6555]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Entrectinib for treating NTRK fusion-positive solid tumours in people 1 month to 11 years [TSID12116]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Ferric maltol for treating iron deficiency anaemia in children and adolescents aged 1 month to 17 years TS ID 11994Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Fosdenopterin for treating molybdenum cofactor deficiency type A (terminated appraisal) (TA1078)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 25 June 2025
Mercaptamine hydrochloride for treating corneal cystine crystal deposits in people 6 months to under 2 years with cystinosis [TSID12261]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy [ID1587]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Teduglutide for treating short bowel syndrome in babies 4 to 12 months [TSID10755]Status:Topic prioritisationProgramme:Technology appraisal guidanceExpected publication date: TBC
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC